KR20060052681A - Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도 - Google Patents

Info

Publication number

KR20060052681A

KR20060052681A KR1020057022431A KR20057022431A KR20060052681A KR 20060052681 A KR20060052681 A KR 20060052681A KR 1020057022431 A KR1020057022431 A KR 1020057022431A KR 20057022431 A KR20057022431 A KR 20057022431A KR 20060052681 A KR20060052681 A KR 20060052681A

Authority

KR

South Korea

Prior art keywords

gitrl

gitr

cells

antibody

nucleic acid

Prior art date

2003-05-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003446 ligand Substances 0.000 title abstract description 23
• 101100425749 Mus musculus Tnfrsf18 gene Proteins 0.000 title description 4
• 238000000034 method Methods 0.000 claims abstract description 186
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 160
• 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims abstract description 99
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 63
• 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 60
• 150000001875 compounds Chemical class 0.000 claims abstract description 59
• 201000011510 cancer Diseases 0.000 claims abstract description 47
• 238000012360 testing method Methods 0.000 claims abstract description 37
• 208000035473 Communicable disease Diseases 0.000 claims abstract description 33
• 238000012216 screening Methods 0.000 claims abstract description 13
• 210000004027 cell Anatomy 0.000 claims description 235
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 212
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 170
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 164
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 164
• 108090000623 proteins and genes Proteins 0.000 claims description 160
• 239000012634 fragment Substances 0.000 claims description 151
• 239000005557 antagonist Substances 0.000 claims description 137
• 108020001507 fusion proteins Proteins 0.000 claims description 101
• 102000037865 fusion proteins Human genes 0.000 claims description 101
• 108091007433 antigens Proteins 0.000 claims description 99
• 102000036639 antigens Human genes 0.000 claims description 99
• 239000000427 antigen Substances 0.000 claims description 98
• 230000014509 gene expression Effects 0.000 claims description 92
• 102000004169 proteins and genes Human genes 0.000 claims description 90
• 230000003472 neutralizing effect Effects 0.000 claims description 80
• 150000007523 nucleic acids Chemical class 0.000 claims description 80
• 239000000556 agonist Substances 0.000 claims description 77
• 102000039446 nucleic acids Human genes 0.000 claims description 75
• 108020004707 nucleic acids Proteins 0.000 claims description 75
• 230000002401 inhibitory effect Effects 0.000 claims description 70
• 150000003384 small molecules Chemical class 0.000 claims description 66
• 230000000694 effects Effects 0.000 claims description 65
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 61
• 230000027455 binding Effects 0.000 claims description 61
• 230000005764 inhibitory process Effects 0.000 claims description 60
• 241000282414 Homo sapiens Species 0.000 claims description 55
• 230000003042 antagnostic effect Effects 0.000 claims description 47
• 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims description 46
• 125000003729 nucleotide group Chemical group 0.000 claims description 38
• 239000002773 nucleotide Substances 0.000 claims description 37
• 230000003993 interaction Effects 0.000 claims description 36
• 239000000523 sample Substances 0.000 claims description 36
• 210000003162 effector t lymphocyte Anatomy 0.000 claims description 34
• 108020004459 Small interfering RNA Proteins 0.000 claims description 32
• 230000035755 proliferation Effects 0.000 claims description 32
• 239000003795 chemical substances by application Substances 0.000 claims description 30
• 230000001965 increasing effect Effects 0.000 claims description 28
• 239000008194 pharmaceutical composition Substances 0.000 claims description 27
• 206010052779 Transplant rejections Diseases 0.000 claims description 26
• 241001465754 Metazoa Species 0.000 claims description 25
• 239000002671 adjuvant Substances 0.000 claims description 25
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
• 210000003289 regulatory T cell Anatomy 0.000 claims description 25
• 108020004999 messenger RNA Proteins 0.000 claims description 23
• 230000000692 anti-sense effect Effects 0.000 claims description 21
• 230000000295 complement effect Effects 0.000 claims description 21
• 239000000203 mixture Substances 0.000 claims description 21
• 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 19
• 230000000903 blocking effect Effects 0.000 claims description 18
• 108020004414 DNA Proteins 0.000 claims description 17
• 208000015181 infectious disease Diseases 0.000 claims description 17
• 239000012646 vaccine adjuvant Substances 0.000 claims description 15
• 229940124931 vaccine adjuvant Drugs 0.000 claims description 15
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
• 229960005486 vaccine Drugs 0.000 claims description 14
• 238000003745 diagnosis Methods 0.000 claims description 13
• 230000000139 costimulatory effect Effects 0.000 claims description 11
• 238000004519 manufacturing process Methods 0.000 claims description 11
• 239000000126 substance Substances 0.000 claims description 11
• 230000009261 transgenic effect Effects 0.000 claims description 11
• 206010020751 Hypersensitivity Diseases 0.000 claims description 9
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
• 230000001580 bacterial effect Effects 0.000 claims description 9
• 230000001939 inductive effect Effects 0.000 claims description 9
• 201000006417 multiple sclerosis Diseases 0.000 claims description 9
• 230000002829 reductive effect Effects 0.000 claims description 9
• 108091034117 Oligonucleotide Proteins 0.000 claims description 8
• 230000007815 allergy Effects 0.000 claims description 8
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
• 208000011231 Crohn disease Diseases 0.000 claims description 7
• 208000006673 asthma Diseases 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 7
• 201000008482 osteoarthritis Diseases 0.000 claims description 7
• 230000003612 virological effect Effects 0.000 claims description 7
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
• 201000004624 Dermatitis Diseases 0.000 claims description 6
• 201000004681 Psoriasis Diseases 0.000 claims description 6
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
• 239000013566 allergen Substances 0.000 claims description 6
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
• 210000002308 embryonic cell Anatomy 0.000 claims description 5
• 210000001082 somatic cell Anatomy 0.000 claims description 5
• 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
• 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
• 201000005000 autoimmune gastritis Diseases 0.000 claims description 4
• 239000013068 control sample Substances 0.000 claims description 4
• 201000002491 encephalomyelitis Diseases 0.000 claims description 4
• 230000002538 fungal effect Effects 0.000 claims description 4
• 244000045947 parasite Species 0.000 claims description 4
• 230000001363 autoimmune Effects 0.000 claims description 3
• 230000003278 mimic effect Effects 0.000 claims description 3
• 230000009467 reduction Effects 0.000 claims description 2
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 57
• 230000003834 intracellular effect Effects 0.000 claims 1
• 102000004196 processed proteins & peptides Human genes 0.000 abstract description 133
• 229920001184 polypeptide Polymers 0.000 abstract description 121
• 102000040430 polynucleotide Human genes 0.000 abstract description 120
• 108091033319 polynucleotide Proteins 0.000 abstract description 120
• 239000002157 polynucleotide Substances 0.000 abstract description 120
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 51
• 201000010099 disease Diseases 0.000 abstract description 46
• 238000011282 treatment Methods 0.000 abstract description 42
• 239000003814 drug Substances 0.000 abstract description 41
• 229940124597 therapeutic agent Drugs 0.000 abstract description 18
• 210000000987 immune system Anatomy 0.000 abstract description 17
• 238000002054 transplantation Methods 0.000 abstract description 17
• 208000027866 inflammatory disease Diseases 0.000 abstract description 16
• 230000008482 dysregulation Effects 0.000 abstract description 11
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract description 10
• 230000001225 therapeutic effect Effects 0.000 abstract description 10
• 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract description 10
• 230000002265 prevention Effects 0.000 abstract description 6
• 239000003862 glucocorticoid Substances 0.000 abstract description 3
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 169
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 169
• 235000018102 proteins Nutrition 0.000 description 84
• 239000003112 inhibitor Substances 0.000 description 51
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 34
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 34
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
• 239000002299 complementary DNA Substances 0.000 description 28
• 239000000047 product Substances 0.000 description 28
• 210000001519 tissue Anatomy 0.000 description 27
• 241000699666 Mus <mouse, genus> Species 0.000 description 26
• 230000028993 immune response Effects 0.000 description 26
• 102000004127 Cytokines Human genes 0.000 description 25
• 108090000695 Cytokines Proteins 0.000 description 25
• 241001529936 Murinae Species 0.000 description 25
• 241000699670 Mus sp. Species 0.000 description 25
• 239000004055 small Interfering RNA Substances 0.000 description 24
• 206010003246 arthritis Diseases 0.000 description 23
• 210000001165 lymph node Anatomy 0.000 description 23
• 238000009396 hybridization Methods 0.000 description 22
• 101000597779 Homo sapiens Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 21
• 210000003719 b-lymphocyte Anatomy 0.000 description 20
• 102000053830 human TNFSF18 Human genes 0.000 description 20
• 210000000612 antigen-presenting cell Anatomy 0.000 description 19
• 229940079593 drug Drugs 0.000 description 19
• 230000006870 function Effects 0.000 description 19
• 230000002441 reversible effect Effects 0.000 description 19
• 108060003951 Immunoglobulin Proteins 0.000 description 18
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 18
• 235000001014 amino acid Nutrition 0.000 description 18
• 102000018358 immunoglobulin Human genes 0.000 description 18
• 230000001404 mediated effect Effects 0.000 description 18
• 102000003390 tumor necrosis factor Human genes 0.000 description 18
• 239000013598 vector Substances 0.000 description 18
• 229940024606 amino acid Drugs 0.000 description 17
• 238000003556 assay Methods 0.000 description 17
• 230000000875 corresponding effect Effects 0.000 description 17
• 150000001413 amino acids Chemical class 0.000 description 16
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 15
• 108010002350 Interleukin-2 Proteins 0.000 description 15
• 102000000588 Interleukin-2 Human genes 0.000 description 15
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 15
• 239000013615 primer Substances 0.000 description 15
• 230000001105 regulatory effect Effects 0.000 description 15
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 15
• 239000013589 supplement Substances 0.000 description 15
• 239000013604 expression vector Substances 0.000 description 14
• 210000000056 organ Anatomy 0.000 description 14
• 102000005962 receptors Human genes 0.000 description 14
• 108020003175 receptors Proteins 0.000 description 14
• 230000004044 response Effects 0.000 description 14
• 230000003827 upregulation Effects 0.000 description 14
• 210000004408 hybridoma Anatomy 0.000 description 13
• 210000004988 splenocyte Anatomy 0.000 description 13
• 239000007787 solid Substances 0.000 description 12
• 210000004881 tumor cell Anatomy 0.000 description 12
• 210000002865 immune cell Anatomy 0.000 description 11
• 238000012544 monitoring process Methods 0.000 description 11
• 238000000746 purification Methods 0.000 description 11
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 11
• 229960002930 sirolimus Drugs 0.000 description 11
• 102000013462 Interleukin-12 Human genes 0.000 description 10
• 108010065805 Interleukin-12 Proteins 0.000 description 10
• 239000012472 biological sample Substances 0.000 description 10
• 238000002474 experimental method Methods 0.000 description 10
• 238000000684 flow cytometry Methods 0.000 description 10
• 238000000338 in vitro Methods 0.000 description 10
• 238000003752 polymerase chain reaction Methods 0.000 description 10
• 230000003393 splenic effect Effects 0.000 description 10
• -1 sulfopropyl Chemical group 0.000 description 10
• 102000000589 Interleukin-1 Human genes 0.000 description 9
• 108010002352 Interleukin-1 Proteins 0.000 description 9
• 108090000176 Interleukin-13 Proteins 0.000 description 9
• 102000003816 Interleukin-13 Human genes 0.000 description 9
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
• 230000036039 immunity Effects 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• 238000011534 incubation Methods 0.000 description 9
• 229960000485 methotrexate Drugs 0.000 description 9
• 238000004393 prognosis Methods 0.000 description 9
• 230000000638 stimulation Effects 0.000 description 9
• 238000006467 substitution reaction Methods 0.000 description 9
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 8
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 8
• 108010036949 Cyclosporine Proteins 0.000 description 8
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 8
• 108090000172 Interleukin-15 Proteins 0.000 description 8
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 8
• 108700012920 TNF Proteins 0.000 description 8
• 241000700605 Viruses Species 0.000 description 8
• 238000007792 addition Methods 0.000 description 8
• 125000000539 amino acid group Chemical group 0.000 description 8
• 229960001265 ciclosporin Drugs 0.000 description 8
• 239000002158 endotoxin Substances 0.000 description 8
• 230000004927 fusion Effects 0.000 description 8
• 230000001506 immunosuppresive effect Effects 0.000 description 8
• 230000006698 induction Effects 0.000 description 8
• 229920006008 lipopolysaccharide Polymers 0.000 description 8
• 241000894007 species Species 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 7
• 206010062016 Immunosuppression Diseases 0.000 description 7
• 102000003812 Interleukin-15 Human genes 0.000 description 7
• 108090000978 Interleukin-4 Proteins 0.000 description 7
• 102000004388 Interleukin-4 Human genes 0.000 description 7
• 239000003146 anticoagulant agent Substances 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 239000003246 corticosteroid Substances 0.000 description 7
• 229930182912 cyclosporin Natural products 0.000 description 7
• 230000003828 downregulation Effects 0.000 description 7
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 7
• 229960000681 leflunomide Drugs 0.000 description 7
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 7
• 239000013612 plasmid Substances 0.000 description 7
• 210000000952 spleen Anatomy 0.000 description 7
• 238000002560 therapeutic procedure Methods 0.000 description 7
• 229940104230 thymidine Drugs 0.000 description 7
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 6
• 229930105110 Cyclosporin A Natural products 0.000 description 6
• 238000002965 ELISA Methods 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 6
• 102100022338 Integrin alpha-M Human genes 0.000 description 6
• 102100022297 Integrin alpha-X Human genes 0.000 description 6
• 102000003814 Interleukin-10 Human genes 0.000 description 6
• 108090000174 Interleukin-10 Proteins 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• 108020004511 Recombinant DNA Proteins 0.000 description 6
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 230000005784 autoimmunity Effects 0.000 description 6
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 6
• 229960002170 azathioprine Drugs 0.000 description 6
• 239000011230 binding agent Substances 0.000 description 6
• 230000033228 biological regulation Effects 0.000 description 6
• 230000003915 cell function Effects 0.000 description 6
• 229960001334 corticosteroids Drugs 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 238000001514 detection method Methods 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 239000003102 growth factor Substances 0.000 description 6
• 238000007901 in situ hybridization Methods 0.000 description 6
• 230000002757 inflammatory effect Effects 0.000 description 6
• 238000001990 intravenous administration Methods 0.000 description 6
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 238000003753 real-time PCR Methods 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• 210000001541 thymus gland Anatomy 0.000 description 6
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
• 102100032912 CD44 antigen Human genes 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 5
• 241000725303 Human immunodeficiency virus Species 0.000 description 5
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 5
• 108010076504 Protein Sorting Signals Proteins 0.000 description 5
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 5
• 230000009471 action Effects 0.000 description 5
• 239000002260 anti-inflammatory agent Substances 0.000 description 5
• 230000000890 antigenic effect Effects 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 150000001720 carbohydrates Chemical class 0.000 description 5
• 230000004663 cell proliferation Effects 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 238000007796 conventional method Methods 0.000 description 5
• 210000004443 dendritic cell Anatomy 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 239000003018 immunosuppressive agent Substances 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 101150028395 perC gene Proteins 0.000 description 5
• NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 5
• 230000004936 stimulating effect Effects 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 4
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 4
• 102100032937 CD40 ligand Human genes 0.000 description 4
• 108091026890 Coding region Proteins 0.000 description 4
• 108010087819 Fc receptors Proteins 0.000 description 4
• 102000009109 Fc receptors Human genes 0.000 description 4
• 102000005720 Glutathione transferase Human genes 0.000 description 4
• 108010070675 Glutathione transferase Proteins 0.000 description 4
• 208000009329 Graft vs Host Disease Diseases 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 4
• 102000004560 Interleukin-12 Receptors Human genes 0.000 description 4
• 108010017515 Interleukin-12 Receptors Proteins 0.000 description 4
• 102000003810 Interleukin-18 Human genes 0.000 description 4
• 108090000171 Interleukin-18 Proteins 0.000 description 4
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 4
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 4
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 4
• 102000043131 MHC class II family Human genes 0.000 description 4
• 108091054438 MHC class II family Proteins 0.000 description 4
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 4
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 108091008874 T cell receptors Proteins 0.000 description 4
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 4
• 102000002933 Thioredoxin Human genes 0.000 description 4
• 102000002689 Toll-like receptor Human genes 0.000 description 4
• 108020000411 Toll-like receptor Proteins 0.000 description 4
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 229940124599 anti-inflammatory drug Drugs 0.000 description 4
• 230000003110 anti-inflammatory effect Effects 0.000 description 4
• 239000011324 bead Substances 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 238000002648 combination therapy Methods 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 230000009368 gene silencing by RNA Effects 0.000 description 4
• 208000024908 graft versus host disease Diseases 0.000 description 4
• 230000003394 haemopoietic effect Effects 0.000 description 4
• 210000002216 heart Anatomy 0.000 description 4
• 102000047758 human TNFRSF18 Human genes 0.000 description 4
• 230000008629 immune suppression Effects 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 229960001428 mercaptopurine Drugs 0.000 description 4
• 238000010172 mouse model Methods 0.000 description 4
• 239000002987 primer (paints) Substances 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 4
• 229960001940 sulfasalazine Drugs 0.000 description 4
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 4
• 229960000235 temsirolimus Drugs 0.000 description 4
• 108060008226 thioredoxin Proteins 0.000 description 4
• 229940094937 thioredoxin Drugs 0.000 description 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
• 201000009030 Carcinoma Diseases 0.000 description 3
• 102000014914 Carrier Proteins Human genes 0.000 description 3
• 102000053642 Catalytic RNA Human genes 0.000 description 3
• 108090000994 Catalytic RNA Proteins 0.000 description 3
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
• 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 3
• 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 3
• 108010008165 Etanercept Proteins 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 108700024394 Exon Proteins 0.000 description 3
• 241000233866 Fungi Species 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 3
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 3
• 108090000177 Interleukin-11 Proteins 0.000 description 3
• 102000003815 Interleukin-11 Human genes 0.000 description 3
• 108050003558 Interleukin-17 Proteins 0.000 description 3
• 102000013691 Interleukin-17 Human genes 0.000 description 3
• 102100030703 Interleukin-22 Human genes 0.000 description 3
• 108090001005 Interleukin-6 Proteins 0.000 description 3
• 102000004889 Interleukin-6 Human genes 0.000 description 3
• 108010002586 Interleukin-7 Proteins 0.000 description 3
• 108090001007 Interleukin-8 Proteins 0.000 description 3
• 102000004890 Interleukin-8 Human genes 0.000 description 3
• 208000003456 Juvenile Arthritis Diseases 0.000 description 3
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
• 102000008072 Lymphokines Human genes 0.000 description 3
• 108010074338 Lymphokines Proteins 0.000 description 3
• 241000699660 Mus musculus Species 0.000 description 3
• 238000012408 PCR amplification Methods 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 230000006052 T cell proliferation Effects 0.000 description 3
• 230000005867 T cell response Effects 0.000 description 3
• 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 3
• 230000003321 amplification Effects 0.000 description 3
• 230000002785 anti-thrombosis Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 108091008324 binding proteins Proteins 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 208000019069 chronic childhood arthritis Diseases 0.000 description 3
• 229940111134 coxibs Drugs 0.000 description 3
• 239000012228 culture supernatant Substances 0.000 description 3
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 229940073621 enbrel Drugs 0.000 description 3
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 238000007429 general method Methods 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 238000010324 immunological assay Methods 0.000 description 3
• 229960003444 immunosuppressant agent Drugs 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 108010074109 interleukin-22 Proteins 0.000 description 3
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 3
• 238000011813 knockout mouse model Methods 0.000 description 3
• 230000021633 leukocyte mediated immunity Effects 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
• 229960004963 mesalazine Drugs 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 229960004866 mycophenolate mofetil Drugs 0.000 description 3
• 238000003199 nucleic acid amplification method Methods 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 238000011002 quantification Methods 0.000 description 3
• 238000003259 recombinant expression Methods 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 229920005989 resin Polymers 0.000 description 3
• 239000011347 resin Substances 0.000 description 3
• 230000000284 resting effect Effects 0.000 description 3
• 238000004007 reversed phase HPLC Methods 0.000 description 3
• 108091092562 ribozyme Proteins 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 230000000392 somatic effect Effects 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 230000001629 suppression Effects 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
• 230000002537 thrombolytic effect Effects 0.000 description 3
• 230000002992 thymic effect Effects 0.000 description 3
• 210000001685 thyroid gland Anatomy 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 238000011830 transgenic mouse model Methods 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
• 208000030767 Autoimmune encephalitis Diseases 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 108010029697 CD40 Ligand Proteins 0.000 description 2
• 101150013553 CD40 gene Proteins 0.000 description 2
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
• 241000557626 Corvus corax Species 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 108010041356 Estrogen Receptor beta Proteins 0.000 description 2
• 102100029951 Estrogen receptor beta Human genes 0.000 description 2
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
• 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
• 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
• 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
• 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
• 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 2
• 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 208000029462 Immunodeficiency disease Diseases 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
• 102100022339 Integrin alpha-L Human genes 0.000 description 2
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
• 102000049772 Interleukin-16 Human genes 0.000 description 2
• 101800003050 Interleukin-16 Proteins 0.000 description 2
• 206010024229 Leprosy Diseases 0.000 description 2
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 108091054437 MHC class I family Proteins 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 108010035766 P-Selectin Proteins 0.000 description 2
• 102100023472 P-selectin Human genes 0.000 description 2
• 239000012826 P38 inhibitor Substances 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• 241000233805 Phoenix Species 0.000 description 2
• 108010003541 Platelet Activating Factor Proteins 0.000 description 2
• 229920002873 Polyethylenimine Polymers 0.000 description 2
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
• 102100038358 Prostate-specific antigen Human genes 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 101100431670 Rattus norvegicus Ybx3 gene Proteins 0.000 description 2
• 241000607142 Salmonella Species 0.000 description 2
• 101000935814 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Periplasmic beta-glucosidase Proteins 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 108091027967 Small hairpin RNA Proteins 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 229940123155 T cell inhibitor Drugs 0.000 description 2
• 230000024932 T cell mediated immunity Effects 0.000 description 2
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
• 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 239000000464 adrenergic agent Substances 0.000 description 2
• 230000001270 agonistic effect Effects 0.000 description 2
• JMLGXYWHNOKLBE-HOTXNYTESA-A alicaforsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 JMLGXYWHNOKLBE-HOTXNYTESA-A 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 229960004676 antithrombotic agent Drugs 0.000 description 2
• 230000007416 antiviral immune response Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 229960000590 celecoxib Drugs 0.000 description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
• 229960002436 cladribine Drugs 0.000 description 2
• 239000004074 complement inhibitor Substances 0.000 description 2
• 108010047295 complement receptors Proteins 0.000 description 2
• 102000006834 complement receptors Human genes 0.000 description 2
• 230000004940 costimulation Effects 0.000 description 2
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 230000002222 downregulating effect Effects 0.000 description 2
• 230000002500 effect on skin Effects 0.000 description 2
• 206010014599 encephalitis Diseases 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 239000002532 enzyme inhibitor Substances 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 230000001605 fetal effect Effects 0.000 description 2
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical class FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 2
• 102000054751 human RUNX1T1 Human genes 0.000 description 2
• 229960004171 hydroxychloroquine Drugs 0.000 description 2
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 229940072221 immunoglobulins Drugs 0.000 description 2
• 230000007233 immunological mechanism Effects 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 230000008611 intercellular interaction Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 229940008228 intravenous immunoglobulins Drugs 0.000 description 2
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 238000007834 ligase chain reaction Methods 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 210000003563 lymphoid tissue Anatomy 0.000 description 2
• 229940124302 mTOR inhibitor Drugs 0.000 description 2
• 210000001161 mammalian embryo Anatomy 0.000 description 2
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 210000003200 peritoneal cavity Anatomy 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• 239000003428 phospholipase inhibitor Substances 0.000 description 2
• 210000002381 plasma Anatomy 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 229960005205 prednisolone Drugs 0.000 description 2
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 230000009696 proliferative response Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 239000003379 purinergic P1 receptor agonist Substances 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 201000003068 rheumatic fever Diseases 0.000 description 2
• 238000003345 scintillation counting Methods 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 102000035160 transmembrane proteins Human genes 0.000 description 2
• 108091005703 transmembrane proteins Proteins 0.000 description 2
• 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 2
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 241000701447 unidentified baculovirus Species 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
• YXBQLONCIPUQKO-UJPOAAIJSA-N (1r)-1-[(3ar,5r,6s,6ar)-6-[3-(dimethylamino)propoxy]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol Chemical compound O1C(C)(C)O[C@@H]2[C@@H](OCCCN(C)C)[C@@H]([C@H](O)CO)O[C@@H]21 YXBQLONCIPUQKO-UJPOAAIJSA-N 0.000 description 1
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
• GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
• SZXUTTGMFUSMCE-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)pyridine Chemical class C1=CNC(C=2N=CC=CC=2)=N1 SZXUTTGMFUSMCE-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
• NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
• NVOYVOBDTVTBDX-AGUVMIOSSA-N 8g15t83e6i Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 NVOYVOBDTVTBDX-AGUVMIOSSA-N 0.000 description 1
• 102100026445 A-kinase anchor protein 17A Human genes 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 241000244186 Ascaris Species 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 241000711404 Avian avulavirus 1 Species 0.000 description 1
• 230000003844 B-cell-activation Effects 0.000 description 1
• 241001037822 Bacillus bacterium Species 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 241000335423 Blastomyces Species 0.000 description 1
• 241000588832 Bordetella pertussis Species 0.000 description 1
• 241000589969 Borreliella burgdorferi Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
• 108010041397 CD4 Antigens Proteins 0.000 description 1
• 101150071146 COX2 gene Proteins 0.000 description 1
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
• 229940045513 CTLA4 antagonist Drugs 0.000 description 1
• 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
• 101100115215 Caenorhabditis elegans cul-2 gene Proteins 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 206010007134 Candida infections Diseases 0.000 description 1
• 241000712083 Canine morbillivirus Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 108090000426 Caspase-1 Proteins 0.000 description 1
• 241001227713 Chiron Species 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• 241001647372 Chlamydia pneumoniae Species 0.000 description 1
• 206010008685 Chondritis Diseases 0.000 description 1
• 208000002691 Choroiditis Diseases 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 241000193449 Clostridium tetani Species 0.000 description 1
• 108091033380 Coding strand Proteins 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 108010062580 Concanavalin A Proteins 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 241000759568 Corixa Species 0.000 description 1
• 241000711573 Coronaviridae Species 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
• 241000223935 Cryptosporidium Species 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 108010041986 DNA Vaccines Proteins 0.000 description 1
• 239000003155 DNA primer Substances 0.000 description 1
• 229940021995 DNA vaccine Drugs 0.000 description 1
• 208000001840 Dandruff Diseases 0.000 description 1
• 206010011891 Deafness neurosensory Diseases 0.000 description 1
• 208000027219 Deficiency disease Diseases 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 238000009007 Diagnostic Kit Methods 0.000 description 1
• 241000255925 Diptera Species 0.000 description 1
• QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
• 208000019872 Drug Eruptions Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 208000032274 Encephalopathy Diseases 0.000 description 1
• 102400000792 Endothelial monocyte-activating polypeptide 2 Human genes 0.000 description 1
• 241000991587 Enterovirus C Species 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 241000710803 Equine arteritis virus Species 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 208000009386 Experimental Arthritis Diseases 0.000 description 1
• 101150021185 FGF gene Proteins 0.000 description 1
• 108010054218 Factor VIII Proteins 0.000 description 1
• 102000001690 Factor VIII Human genes 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 241000711475 Feline infectious peritonitis virus Species 0.000 description 1
• 241000714165 Feline leukemia virus Species 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 229940123414 Folate antagonist Drugs 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 108010015274 GW 3333 Proteins 0.000 description 1
• 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 241000224466 Giardia Species 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 229920002683 Glycosaminoglycan Polymers 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
• 241000606768 Haemophilus influenzae Species 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 241000711549 Hepacivirus C Species 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 206010019755 Hepatitis chronic active Diseases 0.000 description 1
• 241000709721 Hepatovirus A Species 0.000 description 1
• 241000606831 Histophilus somni Species 0.000 description 1
• 241000228402 Histoplasma Species 0.000 description 1
• 101000718019 Homo sapiens A-kinase anchor protein 17A Proteins 0.000 description 1
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
• 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
• 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
• 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 1
• 101001008498 Homo sapiens Luc7-like protein 3 Proteins 0.000 description 1
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
• 101000611655 Homo sapiens Prolactin regulatory element-binding protein Proteins 0.000 description 1
• 101000798700 Homo sapiens Transmembrane protease serine 3 Proteins 0.000 description 1
• 101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 241000701806 Human papillomavirus Species 0.000 description 1
• 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 238000012404 In vitro experiment Methods 0.000 description 1
• 241000702626 Infectious bursal disease virus Species 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
• 108010005716 Interferon beta-1a Proteins 0.000 description 1
• 108010005714 Interferon beta-1b Proteins 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 102000004556 Interleukin-15 Receptors Human genes 0.000 description 1
• 108010017535 Interleukin-15 Receptors Proteins 0.000 description 1
• 102000004557 Interleukin-18 Receptors Human genes 0.000 description 1
• 108010017537 Interleukin-18 Receptors Proteins 0.000 description 1
• 102100035017 Interleukin-18-binding protein Human genes 0.000 description 1
• 101710205006 Interleukin-18-binding protein Proteins 0.000 description 1
• 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 description 1
• 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 102000000646 Interleukin-3 Human genes 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 102000000743 Interleukin-5 Human genes 0.000 description 1
• 102000000704 Interleukin-7 Human genes 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 102000000585 Interleukin-9 Human genes 0.000 description 1
• 208000029523 Interstitial Lung disease Diseases 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
• 241000235649 Kluyveromyces Species 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 241000589929 Leptospira interrogans Species 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
• 102100027434 Luc7-like protein 3 Human genes 0.000 description 1
• 208000008771 Lymphadenopathy Diseases 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
• 241001293418 Mannheimia haemolytica Species 0.000 description 1
• 241000712079 Measles morbillivirus Species 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
• 101710164353 Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 1
• 241000588655 Moraxella catarrhalis Species 0.000 description 1
• 102100034256 Mucin-1 Human genes 0.000 description 1
• 108010008707 Mucin-1 Proteins 0.000 description 1
• 102100023123 Mucin-16 Human genes 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241000711386 Mumps virus Species 0.000 description 1
• 241000204022 Mycoplasma gallisepticum Species 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 102000047918 Myelin Basic Human genes 0.000 description 1
• 101710107068 Myelin basic protein Proteins 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
• 206010054107 Nodule Diseases 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
• 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
• 101150000187 PTGS2 gene Proteins 0.000 description 1
• 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
• 241000606856 Pasteurella multocida Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000015439 Phospholipases Human genes 0.000 description 1
• 108010064785 Phospholipases Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 208000007452 Plasmacytoma Diseases 0.000 description 1
• 108010001014 Plasminogen Activators Proteins 0.000 description 1
• 102000001938 Plasminogen Activators Human genes 0.000 description 1
• 241000233872 Pneumocystis carinii Species 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
• 208000003971 Posterior uveitis Diseases 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• 102100040658 Prolactin regulatory element-binding protein Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 208000010362 Protozoan Infections Diseases 0.000 description 1
• 241000711798 Rabies lyssavirus Species 0.000 description 1
• 241000725643 Respiratory syncytial virus Species 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 206010051497 Rhinotracheitis Diseases 0.000 description 1
• 241000711897 Rinderpest morbillivirus Species 0.000 description 1
• 241000702670 Rotavirus Species 0.000 description 1
• 241000710799 Rubella virus Species 0.000 description 1
• 241001138501 Salmonella enterica Species 0.000 description 1
• 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
• 241000242678 Schistosoma Species 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
• 241000607768 Shigella Species 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 241000713311 Simian immunodeficiency virus Species 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 208000006045 Spondylarthropathies Diseases 0.000 description 1
• 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
• 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
• 241000193985 Streptococcus agalactiae Species 0.000 description 1
• 241000193998 Streptococcus pneumoniae Species 0.000 description 1
• 241000193996 Streptococcus pyogenes Species 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
• 108010010517 TADG-12 serine protease Proteins 0.000 description 1
• 101150109894 TGFA gene Proteins 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 241000223997 Toxoplasma gondii Species 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102100032454 Transmembrane protease serine 3 Human genes 0.000 description 1
• 241000224526 Trichomonas Species 0.000 description 1
• 241001489151 Trichuris Species 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 108091005956 Type II transmembrane proteins Proteins 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 229940124674 VEGF-R inhibitor Drugs 0.000 description 1
• 206010046914 Vaginal infection Diseases 0.000 description 1
• 201000008100 Vaginitis Diseases 0.000 description 1
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 241000607626 Vibrio cholerae Species 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 229960000711 alprostadil Drugs 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 229960003556 aminophylline Drugs 0.000 description 1
• FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
• 229950010999 amiprilose Drugs 0.000 description 1
• 230000003941 amyloidogenesis Effects 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 239000010775 animal oil Substances 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 230000007503 antigenic stimulation Effects 0.000 description 1
• 208000002399 aphthous stomatitis Diseases 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 201000004982 autoimmune uveitis Diseases 0.000 description 1
• 229940003504 avonex Drugs 0.000 description 1
• QQOBRRFOVWGIMD-OJAKKHQRSA-N azaribine Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C(=O)NC(=O)C=N1 QQOBRRFOVWGIMD-OJAKKHQRSA-N 0.000 description 1
• 229950010054 azaribine Drugs 0.000 description 1
• 229960001212 bacterial vaccine Drugs 0.000 description 1
• OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
• 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 229940021459 betaseron Drugs 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 229960004436 budesonide Drugs 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 235000020289 caffè mocha Nutrition 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• 201000003984 candidiasis Diseases 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 238000005341 cation exchange Methods 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 229960003115 certolizumab pegol Drugs 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960003677 chloroquine Drugs 0.000 description 1
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
• 229960003405 ciprofloxacin Drugs 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 238000003501 co-culture Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 230000010485 coping Effects 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 229940029030 dendritic cell vaccine Drugs 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
• 239000008355 dextrose injection Substances 0.000 description 1
• 238000013154 diagnostic monitoring Methods 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
• POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000003602 elastase inhibitor Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 210000003315 endocardial cell Anatomy 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
• 229960000301 factor viii Drugs 0.000 description 1
• 229960004979 fampridine Drugs 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
• 229960004369 flufenamic acid Drugs 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• 238000010230 functional analysis Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 238000001641 gel filtration chromatography Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000011223 gene expression profiling Methods 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 229940047650 haemophilus influenzae Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 102000056549 human Fv Human genes 0.000 description 1
• 108700005872 human Fv Proteins 0.000 description 1
• 102000056003 human IL15 Human genes 0.000 description 1
• 102000043959 human IL18 Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
• 229960002240 iloprost Drugs 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 108010023260 immunoglobulin Fv Proteins 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 210000003000 inclusion body Anatomy 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000013546 insoluble monolayer Substances 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 102000044166 interleukin-18 binding protein Human genes 0.000 description 1
• 108010070145 interleukin-18 binding protein Proteins 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
• 229960001888 ipratropium Drugs 0.000 description 1
• 208000002551 irritable bowel syndrome Diseases 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 210000003125 jurkat cell Anatomy 0.000 description 1
• 229960004958 ketotifen Drugs 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 239000012035 limiting reagent Substances 0.000 description 1
• 239000004973 liquid crystal related substance Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 230000001050 lubricating effect Effects 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 208000018555 lymphatic system disease Diseases 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 108010000525 member 1 small inducible cytokine subfamily E Proteins 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 229960000282 metronidazole Drugs 0.000 description 1
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 244000000010 microbial pathogen Species 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 229960004023 minocycline Drugs 0.000 description 1
• DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical compound ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 201000009240 nasopharyngitis Diseases 0.000 description 1
• 230000002956 necrotizing effect Effects 0.000 description 1
• 229960004398 nedocromil Drugs 0.000 description 1
• RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
• 230000012177 negative regulation of immune response Effects 0.000 description 1
• 230000006213 negative regulation of lymphocyte proliferation Effects 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 238000002966 oligonucleotide array Methods 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 238000010397 one-hybrid screening Methods 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 230000003071 parasitic effect Effects 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 229940051027 pasteurella multocida Drugs 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 102000014187 peptide receptors Human genes 0.000 description 1
• 108010011903 peptide receptors Proteins 0.000 description 1
• 210000000134 pericardial cell Anatomy 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000003024 peritoneal macrophage Anatomy 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 230000002974 pharmacogenomic effect Effects 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 125000000405 phenylalanyl group Chemical group 0.000 description 1
• 229960002895 phenylbutazone Drugs 0.000 description 1
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
• 229940127126 plasminogen activator Drugs 0.000 description 1
• 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
• 239000002574 poison Substances 0.000 description 1
• 231100000614 poison Toxicity 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 230000017363 positive regulation of growth Effects 0.000 description 1
• 231100000683 possible toxicity Toxicity 0.000 description 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 229940043274 prophylactic drug Drugs 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 239000012460 protein solution Substances 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000003014 reinforcing effect Effects 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 229960002052 salbutamol Drugs 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 235000017709 saponins Nutrition 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
• 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 235000020254 sheep milk Nutrition 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 239000008354 sodium chloride injection Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 201000005671 spondyloarthropathy Diseases 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229960000195 terbutaline Drugs 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229960000103 thrombolytic agent Drugs 0.000 description 1
• RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
• 208000008732 thymoma Diseases 0.000 description 1
• XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
• 229960000488 tizanidine Drugs 0.000 description 1
• 230000024664 tolerance induction Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
• 229960000401 tranexamic acid Drugs 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 239000002525 vasculotropin inhibitor Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 229940118696 vibrio cholerae Drugs 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 229960004854 viral vaccine Drugs 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 210000004885 white matter Anatomy 0.000 description 1
• 230000002087 whitening effect Effects 0.000 description 1
• 229940075420 xanthine Drugs 0.000 description 1
• MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
• 229960005332 zileuton Drugs 0.000 description 1